4-year duration of SLIT with dust mite seems like the optimal choice

Up to 40% of the world's population has been diagnosed with an allergic disease. The most prevalent allergy is to house dust mites (http://buff.ly/1jSF5Y6). Data on the long-term effects of sublingual immunotherapy (SLIT) are sparse, and the optimal duration of treatment is a matter of debate.

In this prospective open controlled study, the patients with respiratory allergy who were monosensitized to mites (allergic to dust mites only) were followed for 15 years.

78 patients were enrolled, and 59 completed the study. In the 12 control subjects no relevant change in clinical scores was seen throughout the study.

In the patients receiving SLIT for 3 years, the clinical benefit persisted for 7 years. In those receiving immunotherapy for 4 or 5 years, the clinical benefit persisted for 8 years.

New sensitizations occurred in all the control subjects over 15 years and in less than a quarter of the patients receiving SLIT (21%, 12%, and 11%, respectively).

It can be suggested that a 4-year duration of SLIT is the optimal choice because it induces a long-lasting clinical improvement similar to that seen with a 5-year course and greater than that of a 3-year vaccination.

Dust mite allergen avoidance. The main allergen is in the dust mite feces. Use 3 control measures for 3-6 months to see an effect on the allergy symptoms (click to enlarge the image).


Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. J Allergy Clin Immunol. 2010 Oct 7.

House dust mite sensitization in toddlers predicts wheeze at age 12 years (JACI, 2011).

Sublingual immunotherapy (SLIT) not effective in house dust mite-allergic children in primary care http://goo.gl/EdFHJ

Dust mite, more than foods, may be the major cause of allergic atopic dermatitis (http://goo.gl/48TgN).

Dust mite SLIT in children with allergic rhinitis and asthma: compliance 86%, symptoms improved in 65% of patients http://buff.ly/1lJEB5T

No comments:

Post a Comment